Biocryst Pharmaceuticals (BCRX) Tax Provisions (2021 - 2026)

Biocryst Pharmaceuticals has reported Tax Provisions for 6 years, with the latest figure at $1.0 million in Q1 2026.

• For the quarter ending Q1 2026, Tax Provisions rose 38.29% year-over-year to $1.0 million; the trailing twelve-month figure through Mar 2026 stood at $3.8 million (up 66.43% YoY), and the FY2025 full-year result was $3.5 million, up 83.19% from the prior year.
• Tax Provisions for Q1 2026 stood at $1.0 million, down from $2.2 million in the prior quarter.
• The five-year high for Tax Provisions was $2.2 million in Q4 2025, with the low at -$1.4 million in Q4 2023.
• Historically, Tax Provisions has averaged $559058.8 across 5 years, with a median of $671000.0 in 2023.
• Annual changes were most pronounced in 2023 — Tax Provisions plunged 1982.89% — and 2025, when it soared 714.53%.
• Biocryst Pharmaceuticals' Tax Provisions stood at $76000.0 in 2022, then sank by 1982.89% to -$1.4 million in 2023, then surged by 156.18% to $804000.0 in 2024, then soared by 170.15% to $2.2 million in 2025, then sank by 53.78% to $1.0 million in 2026.
• The last three Tax Provisions figures came in at $1.0 million (Q1 2026), $2.2 million (Q4 2025), and -$769000.0 (Q3 2025), per Business Quant data.